Medicare AdvantageCoverageMedium impact
MA08.001h, Vedolizumab (Entyvio®) for Injection for Intravenous Use
Independence Blue Cross·Gastroenterology·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.001h for Vedolizumab (Entyvio®) injections has been reissued with an effective date of November 26, 2025. This is a pharmacy policy update that may affect coverage criteria or prior authorization requirements for this inflammatory bowel disease medication.
Action Required
By November 26, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing guidelines for Vedolizumab (Entyvio®) injections. Update billing procedures and prior authorization workflows as needed based on the complete policy content.